Skip to main content
Equibles
SGP logo

SGP · SpyGlass Pharma, Inc.

Track SGP — free

Use SGP with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research SGP.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$27.52 +0.21 (+0.77%) At close · Sep 11
Russell 2000 member Rebalance outlook locked
Market Cap
$920.49M
Shares
33.45M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$27.52 Open$27.68 Day$27.29–28.40 Available close range$17.56–29.68 Avg vol 30d80K Short int1.1M · 3.3% float · 15.8d Short vol89% Last earningsMay 26, 2026 DataFeb 2026–Sep 2026 Filing10-Q · Aug 6

The closing range uses available history since Feb 6, 2026; less than a full year is stored.

Up next

Latest filing: 10-Q
filed Aug 6, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$56.05M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-5.4%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$223.14M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+1,368.2%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
3.3%
Latest settlement · 15.8 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Neutral Momentum Strong Sentiment Bullish Fundamentals Poor Quant / Vol Very High
Market backdrop VIX 15.8 · calm Equity put/call 0.58
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 50-day avg +15%
above
RSI (14) 59
neutral
MACD trend Negative
52-week position 82%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Strong
1-month return +9%
trailing
6-month return +6%
trailing
Relative strength −12%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Accumulating
+49% holders QoQ · +22 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
3.28% of float · ▼ -3.5% MoM · 15.8 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
52 holders — 13F breadth
Squeeze score 64
elevated · 0–100
Fundamentals
Poor
EPS growth −10%
Y/Y
Free cash flow $-33.5M
Quant / Vol
risk profile
Very High
Volatility 63%
annualized · 1-yr
Max drawdown −41%
past year
ATR 5.0%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
1 · 4 · 1
50 / 200-day cross
No cross Neutral
Price vs 50-day avg
+15% Bullish
RSI (14)
59 Neutral
MACD trend
Negative Bearish
52-week position
82% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Accumulating
+49% holders QoQ · +22 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
3.28% of float · ▼ -3.5% MoM · 15.8 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
52 holders — 13F breadth
Price context
position in its available closing range
Range low $18 Now $28 · 82% Range high $30
vs 50-day avg +15%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
SGP
SpyGlass Pharma, Inc.
this stock
$920.49M — — — 3.3%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $130.64B +13.7% +46.2% 30.0 1.8%
REGN
Regeneron Pharmaceuticals, Inc.
 $80.46B +1.2% +20.8% 19.4 2.5%
ARGX
Argenx SE
 $61.22B +17.1% — — 2.0%
MRNA
Moderna, Inc.
 $57.48B +388.2% +4.3% — 9.8%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
52
% held
78.1%
Net QoQ
+769.5K sh
Top holder
RA CAPITAL MANAGEMENT, L.…
Held Float
View
Held by Funds
Fund positions
66
View
Short & Settlement
Short Interest Falling
Shares short
1.1M
Days to cover
15.8d
Change
-39.9K sh
View
Short Volume
Short vol %
89%
As of
Sep 11, 2026
Short Total
View
Fails to Deliver
FTD shares
358
Value
$9.0K
As of
Aug 13, 2026
View
Off-Exchange
Off-exchange %
36.0%
Week of
Aug 3, 2026
Off-exch Lit
View
Financials
Financials
Net income (FY)
$-39.9M
EPS diluted
$-17.98
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 6, 2026
This year
11
View
Exempt Offerings
Offering
$75.0M
Filed
Jun 5, 2025
View
Earnings & Events
Earnings Calls
Last call
Jun 10, 2026
View

Performance

5D 20D 120D MTD YTD
SGP -5.1% +9.3% +5.9% +5.4% —
SPY -1.2% -1.8% +17.8% -0.4% +12.1%
vs SPY -3.9% +11.1% -12.0% +5.8% —
Key facts CIK 1778922 CUSIP 85220G109 13F (30d) 19 filings 19 filers Visit website Investor relations